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Quebecol is a polyphenolic compound initially isolated from Canadian maple syrup in 
2011. Recently, our group demonstrated in a macrophage model that quebecol inhibits the 
secretion of pro-inflammatory cytokines and reduces the activation of the NF-kB 
transcription factor. In this study, we further explored the therapeutic potential of quebecol 
against periodontal disease, an inflammatory disorder of bacterial origin affecting the 
tooth-supporting tissues. More specifically, the effects of this natural compound on matrix 
metalloproteinase (MMP) activity and macrophage secretion, as well as on the 
mineralization activity of osteoblasts (bone-forming cells), were investigated. Results 
showed that exposing LPS-treated macrophages to quebecol led to a significant decrease 
in the secretion of MMP-8 and MMP-9. In addition, quebecol dose-dependently inhibited 
the catalytic activity of MMP-9. Quebecol also enhanced the mineralization activity of 
osteoblasts. This study brought forward additional evidence to support the potential of 







Periodontitis, a destructive form of periodontal disease that causes permanent damage to 
the periodontium, is a widespread pathology that currently ranks as the sixth most common 
chronic inflammatory disorder in the world.1 As such, it remains to this day a worldwide 
public health concern with major economic and social burdens. Periodontitis results from 
an uncontrolled inflammatory response of mucosal and immune cells to specific gram-
negative strictly anaerobic bacterial species colonizing the subgingival sites as a biofilm.2, 
3 Evolution of this pathology leads to the progressive destruction of periodontal connective 
tissue and alveolar bone that may cause tooth loss.1 This pathogenic process involves the 
expression and secretion by resident and infiltrating cells of the periodontium of a wide 
variety of pro-inflammatory mediators and matrix metalloproteinases (MMPs) that 
modulate periodontal tissue destruction and perpetuate the pathology.4-6  
 
MMPs, a family of host-derived calcium-dependent zinc-containing proteolytic enzymes, 
are involved in the degradation of extracellular matrix (ECM) components, such as 
collagen, fibronectin, laminin, and elastin, during both normal and pathological 
conditions.7 MMPs are produced by the major cell types found in periodontal tissue, 
including epithelial cells, fibroblasts, neutrophils, and macrophages.5, 6 In healthy 
periodontal tissues their expression is quite low and their activity is regulated by 
endogenous molecular agents called tissue inhibitors of metalloproteinases (TIMPs).5, 6 
However, an over-expression of MMPs has been associated to the pathological tissue 
destruction process observed during periodontitis.6, 8, 9 Therefore, the excessive production 
and activity of MMPs has been proposed as a potential target for pharmacological 
intervention in periodontitis.5, 10, 11  
 
MMPs also markedly contribute to alveolar bone loss occurring during periodontitis, which 
is a process triggered by osteoclasts and attributed to the inflammatory nature of the 
disease.12 Osteoblasts, which are cells involved in the process of bone formation, can 
restore the normal bone homeostasis.13, 14 These cells are derived from mesenchymal cells 
and secrete the organic matrix (mostly collagen) and induce calcification during the 
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formation of new bones.13, 14 Targeting osteoblast activity may therefore represent a 
relevant therapeutic strategy against periodontitis. 
 
Quebecol (ethyl 2,3,3-tris(4-hydroxy-3-methoxyphenyl)propan-1-ol; compound 1; Fig. 1a) 
is a polyphenolic compound initially isolated from Canadian maple syrup in 2011.15 It is 
formed during the heating process required to transform the sap of Acer saccharum into 
syrup. In vitro bioassays brought evidence that quebecol may represent a promising 
chemopreventive or chemotherapeutic agent.16-18 Recently, we developed an efficient 
synthesis protocol for quebecol (Fig. 1a)19 and reported its in vitro anti-inflammatory 
activity.20 More precisely, we showed that a treatment of lipopolysaccharide (LPS)-
stimulated human macrophages with quebecol leads to an inhibition of the secretion of two 
pro-inflammatory cytokines (IL-6 and TNF-α), while a reduction of the activation of the 
NF-kB transcription factor was also observed.20 In parallel to our work on quebecol itself, 
twenty related compounds (precursors, isomers, and substructures) were synthesized and 
used in structure-activity relationship studies.20, 21 In brief, these studies showed that 
quebecol (Fig. 1a) and its diarylmethane substructure (compound 3; Fig. 1b) exhibit anti-
inflammatory activity.20, 21 Results also demonstrated that the substitution pattern on the 
aromatic rings of these active structures (compounds 4 and 5; Fig. 1b) led to a slightly 
enhanced activity but higher cytotoxicity.21 It was concluded that the natural product 1 was 
still the most promising anti-inflammatory compound based on biological activity and 
toxicity arguments. 
 
Encouraged by the above results, we wished to further explore the therapeutic potential of 
quebecol against periodontitis by focusing on the two specific therapeutic targets discussed 
above: MMPs and osteoblasts. First, we investigated the ability of quebecol to attenuate 
the secretion of MMPs by LPS-stimulated macrophages and to inhibit the catalytic activity 







Figure 1.  Quebecol and relevant related structures from our previous work. (a) Structure of quebecol and 
accessibility from isolation or synthesis; (b) Relevant bioactive structures identified in our previous structure 






Quebecol and MMP secretion by macrophages 
The effect of quebecol on the in vitro regulation of MMPs was investigated by assessing 
its capacity to impair their secretion in a macrophage model, which represents a leukocyte 
type recognized as an important producer of MMPs in the context of periodontitis. To this 
end, we assessed its effect on the basal and LPS-induced secretion of MMP-3, MMP-8, 
and MMP-9. These three specific MMPs were selected on the basis of their known 
association with active periodontitis.5, 6, 8-10 It is also worth mentioning that these three 
MMPs were those secreted in the highest amount by the U937 macrophages used in this 
study. 
 
The secretion of MMP-3, MMP-8, and MMP-9 by macrophages kept under normal 
conditions or stimulated with A. actinomycetemcomitans LPS is reported in Fig. 2. MMP-
9 was found to be produced in significantly greater amounts than MMP-3 and MMP-8. The 
stimulation of macrophages with LPS did not significantly modify the secretion of MMP-
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3 and MMP-9, while it increased the secretion of MMP-8 by 20.8% (p < 0.001). More 
specifically, LPS-stimulated macrophages secreted 650 ng/mL, 3 109 pg/mL, and 2 354 
pg/mL of MMP-9, MMP-8 and MMP-3, respectively. 
 
 
Figure 2. Effect of A. actinomycetemcomitans LPS on the secretion of MMP-3, MMP-8, and MMP-9 by 
macrophages. Means ± standard deviations of triplicate assays. *: p < 0.001. 
 
We first investigated the effect of quebecol on MMP secretion by macrophages kept under 
normal conditions (without LPS stimulation). When the cells were exposed to the highest 
concentration (500 μM) of quebecol, the secretion of MMP-3, MMP-8, and MMP-9 
significantly decreased by 15.9%, 34.4%, and 26.8% (p < 0.001) (Fig. 3). Quebecol at 
concentrations ≤ 125 μM did not reduce the secretion of any of the MMPs in a significant 
manner.   
 
Then, the same analysis was performed using macrophages that were stimulated with A. 
actinomycetemcomitans LPS in a way to simulate an inflammatory condition. As shown in 
Fig. 3, while only a slight inhibition of MMP-3 secretion by quebecol was observed for 
LPS-stimulated macrophages, significant dose-dependent reductions in the secretion of 
MMP-8 and MMP-9 were caused by the presence of quebecol even at the lowest 
concentration tested (31.25 μM), with an inhibition of 15.2% and 21.4%, respectively. 




Figure 3. Inhibitory effect of quebecol on the secretion of MMP-3, MMP-8, and MMP-9 by macrophages 
stimulated with A. actinomycetemcomitans LPS or not. Means ± standard deviations of triplicate assays. *: 
p < 0.001, #: p < 0.05. 
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Overall, a difference regarding the inhibitory activity of quebecol on the secretion of MMP-
8, MMP-9 and to a lesser extent MMP-3 by macrophages kept under normal conditions or 
stimulated with A. actinomycetemcomitans LPS was observed. Such a selectivity would be 
advantageous regarding a potential clinical use since this natural compound would have a 
minimal impact on healthy gingival tissues. 
 
Quebecol and MMP-9 activity 
Given the interesting results obtained regarding the effect of quebecol on MMP-9 secretion 
and that MMP-9 was produced in high amounts by macrophages, we selected this MMP to 
investigate the effect of quebecol on its catalytic activity.22 As reported in Table 1, 
quebecol reduced the degradation of gelatin by MMP-9 in a dose-dependent manner. More 
specifically, the presence of quebecol at 250 and 500 μM inhibited the activity of MMP-9 
by 42% and 92.6%, respectively. It is interesting to note that while the secretion of this 
MMP by macrophages stayed similar between these two concentrations of quebecol under 
an inflammatory context, an important difference with respect to MMP-9 activity was 
observed. 
 
Table 1. Effect of quebecol on MMP-9 activity. 
Concentration (μM) Relative activity (%) 
0 100 ± 2 
62.5 92.2 ± 0.6 
125 82 ±1* 
250 58 ± 3* 
500 7.4 ± 0.6* 
*: Significantly different from control (no quebecol) at p < 0.001 
 
Quebecol and osteoblast mineralization activity 
An important process involving osteoblasts during bone formation is their mineralization 
activity. It was thus of interest to investigate the effect of quebecol on the mineralization 
activity of SaOS-2 cells by monitoring the formation of extracellular mineral deposits with 
a staining agent (Alizarin Red S) that selectively binds to calcium salts. As shown in Fig. 
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4, the presence of quebecol promoted the formation of calcium deposits that appear as red 
mineralized nodules. More specifically, quebecol, from a concentration of 12.5 μg/mL 
(corresponding to 29.3 μM), dose-dependently promoted the mineralization activity of 
osteoblasts (Fig. 5). A marked increase in mineralization activity was observed at the 
highest concentrations tested. For instance, the presence of quebecol at 100 μg/mL 




Figure 4.  Effect of quebecol on the mineralization activity of SaOS cells. Representative microscopic 





Figure 5. Effect of quebecol on the mineralization activity of SaOS cells as expressed by Alizared red 




Polyphenols are compounds that possess an aromatic ring with at least one hydroxyl group 
and show high heterogeneity in their structure, from simple molecules to complex 
polymers.23 Due to their antimicrobial, antioxidant, and immunomodulatory properties, 
there has been a growing research interest in polyphenols with respect to oral health 
benefits.24-26 A process-derived polyphenolic compound isolated from maple syrup, named 
quebecol after the Canadian province of Quebec (the world’s leading producer of maple-
derived products), has been the topic of several studies.15-21 Based on our recent 
investigations reporting the anti-inflammatory properties of quebecol,20 the present study 
further investigated its potential as a prophylactic and therapeutic agent against 
periodontitis, a widespread chronic inflammatory disease of bacterial origin that affects the 
tooth-supporting tissue. 
 
The continuous, high production of MMPs by infiltrating and resident cells of the 
periodontium triggered by periodontopathogens contributes to connective tissue 
destruction and alveolar bone resorption.6, 8, 9 In fact, it is well known that MMP levels and 
activities are significantly higher in the gingival tissue and gingival crevicular fluid of 
periodontitis-affected individuals than from healthy subjects.6, 8, 9 Therefore, MMP 
inhibitors may have interesting potential for use as an effective therapeutic approach for 
treating periodontitis patients.10-11 Consequently, quebecol was tested for its effect on 
MMP secretion in a macrophage model, as macrophages are potent MMP producers and 
constitute an important part of the inflammatory infiltrate in active periodontal lesions.27 
In the present study, we showed that A. actinomycetemcomitans LPS acts as an inducer of 
the secretion of MMP-8 by macrophages, while it has no effect on the secretion of MMP-
3 and MMP-9. Our results showed that quebecol caused a significant inhibition of the 
secretion of MMP-8 (50.9%) and MMP-9 (34.8%) when the cells were treated with this 
phenolic compound (250 μΜ) in an inflammatory context (stimulation with LPS). MMP-
8 (collagenase-2) and MMP-9 (gelatinase B) are present in high concentrations in inflamed 
periodontitis sites and are strongly associated with the progression of periodontitis.29 
Periodontal therapy (scaling and root planing) has been shown to significantly reduce 
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salivary MMP-8 and MMP-9 levels,30, 31 suggesting that these two MMPs are potential 
markers for monitoring periodontal disease activity. Consequently, the ability of quebecol 
to attenuate the secretion of these two MMPs may contribute to reduced periodontal tissue 
destruction. Although the exact inhibitory mechanism of action of quebecol was not 
investigated, it is likely related to the previously reported capacity of quebecol to impair 
NF-κB activation in macrophages.20 Indeed, previous studies have shown that the 
expression of MMPs by macrophages involves the NF-κB signaling pathway.32, 33 
Moreover, La et al.34 reported that cranberry proanthocyanidins reduce MMP-9 secretion 
in macrophages through the inhibition of NF-κB activation. 
 
To complement the results of the impact of quebecol on MMP secretion by macrophages, 
we assessed its effect on MMP-9 activity. This analysis revealed that the polyphenolic 
compound exerts a marked dose-dependent inhibitory effect on the capacity of MMP-9 to 
degrade its natural substrate (gelatin). Although the mechanism of action remains to be 
elucidated, it can be hypothesized that quebecol, with its four phenol groups, acts as a 
ligand on MMP-9 that either deactivates the zinc ion on the catalytic cycle or blocks the 
access of substrate to the active site of the enzyme. 
 
Since bone formation is instrumental to counterbalance tissue destruction in the context of 
periodontitis, we also studied the effect of quebecol in an in vitro osteoblast model. While 
they secrete collagen and proteins during bone formation, osteoblasts also trigger calcium 
and mineral deposition, leading to the formation of hydroxyapatite on the newly formed 
bone matrix.13, 14 We demonstrated that the mineralization activity of osteoblasts was 
positively affected by quebecol in a dose-dependent fashion, the most important increase 
in the formation of extracellular calcium deposits being observed at the highest 
concentrations tested. It is also noteworthy to mention that results obtained in a parallel 
study led by our group strongly suggest that the enhanced mineralization activity caused 
by quebecol is not due to an effect of this compound on the population of osteoblast cells 
(see Supporting Information). In accordance with our results, polyphenols from green tea 
are also known to promote osteoblastic mineralization.35  
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 In conclusion, when taken together, the results of our present and previous studies20  point 
towards the potential use of quebecol as a promising multi-target therapeutic agent against 
periodontitis and, most likely, other inflammatory disorders. Indeed, at non-cytotoxic 
concentrations, quebecol was found to inhibit the secretion of MMP-8 and MMP-9 in a 
macrophage model (stimulated with LPS), to inhibit the catalytic activity of MMP-9, and 
to stimulate osteoblast mineralization activity, in addition to impairing NF-κB activation 
and IL-6 secretion in macrophages.20 In this regard, studies on the benefits provided by the 
use of oral hygiene products (mouthrinses and chewing gums) or slow periodontal-release 
devices (to be inserted in diseased periodontal sites) containing quebecol are of high 
interest. Given these promising perspectives, we are currently exploring the effect of this 
natural polyphenol on periodontopathogenic bacteria, which represent the second 
contributing factor to periodontitis. Studies on the effect of quebecol on alveolar bone 




Synthesis of quebecol 
Quebecol was synthesized and characterized according to a previously reported protocol.19  
 
Preparation of monocyte-derived macrophages 
U937 human monocytes (ATCC CRL-1593.2) were purchased from the American Type 
Culture Collection (Manassas, VA, USA) and were cultivated under the following 
conditions: RPMI-1640 + 10% heat-inactivated fetal bovine serum (FBS) + 100 µg/mL of 
penicillin G/streptomycin, 37°C, and 5% CO2 atmosphere. In a way to induce their 
differentiation into adherent macrophage-like cells, the monocytes (2.5 x 105 cells/mL) 
were incubated for 48 h in RPMI-10% FBS medium containing 100 ng/mL of phorbol 
myristic acid (PMA, Sigma-Aldrich Canada Ltd, Oakville, ON, Canada), and then 
harvested by scraping. After centrifugation (1200 g for 5 min), the adherent macrophage-
like cells were washed, suspended in RPMI-1% FBS (concentration of 1 x 106 cells/mL), 
and seeded into wells of 12-well microplates (1 x 106 cells/well) which were incubated for 
24 h at 37°C in a 5% CO2 atmosphere. 
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Determination of MMP-3, MMP-8, and MMP-9 secretion by macrophages 
The aforementioned macrophages were treated with two-fold serial dilutions of quebecol 
(500 to 31.25 µM in culture medium) for 2 h prior to stimulation with LPS (1 µg/mL) 
prepared from Aggregatibacter actinomycetemcomitans ATCC 29522 according to a 
previously described protocol.36 A series of macrophages treated with quebecol but not 
stimulated with LPS was also prepared. After a 24 h incubation (37°C, 5% CO2 
atmosphere), the culture supernatants were collected and stored at -20°C until analyzed. 
Cells incubated in culture medium without quebecol and/or LPS were used as negative 
controls. BAY-11-7082 (Selleckchem, Houston, TX, USA) at a concentration of 5 μg/mL 
was used as a positive inhibitory control. Quantification of MMP-3, MMP-8, and MMP-9 
in cell culture supernatants was performed with enzyme-linked immunosorbent assay 
(ELISA) kits (R & D Systems, Minneapolis, MN, USA) used according to the 
manufacturer’s protocols. Absorbance was recorded at 450 nm using a microplate reader 
(Bio-Rad Laboratories, Mississauga, ON, Canada) with a wavelength correction set at 550 
nm. Sensitivities of the commercial ELISA kits were 0.156 ng/mL, 0.058 ng/mL, and 0.313 
ng/mL for MMP-3, MMP-8, and MMP-9, respectively. The concentration of each MMP 
(active + latent forms) was determined in triplicate assays from two independent 
experiments. 
 
Determination of MMP-9 activity 
Human recombinant MMP-9 was purchased from Calbiochem (San Diego, CA, USA) and 
prepared at a concentration of 20 μg/mL in 5 mM Tris HCl (pH 7.5), with 10% glycerol, 
0.1 mM CaCl2 and 0.005% Brij 35. Activation of MMP-9 was performed in 50 mM Tris-
HCl (pH 7.5) with 0.5 mM p-aminophenylmercuric acetate for 1 h at 37°C. Activated 
MMP-9 was diluted to a final concentration of 10 μg/mL in the reaction buffer (50 mM 
Tris-HCl, 5 mM CaCl2, 200 mM NaCl, and 0.2% Brij 35) and was treated with two-fold 
serial dilutions of quebecol (500 to 62.5 µM) or without (control). After 15 min of 
incubation at 25°C, the fluorogenic substrate fluorescein isothiocyanate-labeled DQTM 
gelatin (Molecular Probes, Eugene, OR, USA) was added at a final concentration of 50 
μg/mL. The assay mixtures were incubated in the dark at 37°C for 2 h before the 
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fluorescence was measured with a Synergy 2 microplate reader (BioTek Instruments, 
Winooski, VT, USA), using an excitation wavelength of 490 nm and an emission 
wavelength of 520 nm. Results were reported as % of activity (means ± standard deviations 
of triplicate assays from two independent experiments) from a comparison with the control 
assay without quebecol (set as 100%). 
 
Mineralization activity of osteoblasts  
Human osteogenic sarcoma SaOS-2 cells ATCC HTB-85 were purchased from ATCC and 
routinely cultured at 37°C in an atmosphere of 5% CO2 in McCoy’s 5A medium containing 
2 mM L-glutamine and supplemented with 15% heat-inactivated FBS and 100 µg/ml of 
penicillin G-streptomycin. For the mineralization assay, SaOS-2 cells were cultivated in 
the above culture medium supplemented with the mineralization activation cocktail (MAC) 
composed of 10 mM β-glycerophosphate and 0.2 mM ascorbic acid. The cells were seeded 
at 1 x 105 cells/well in a 96-well microplate and incubated for 24 h at 37°C in an atmosphere 
of 5% CO2. The medium was replaced with fresh medium containing MAC and two-fold 
serial dilutions of quebecol (100 to 1.5625 μg/mL). After 5 days of incubation, cells in the 
wells were fixed with 4% paraformaldehyde and stained with Alizarin Red S (ScienCell 
Research Laboratories, Carlsbad, CA, USA), according to the manufacturer’s protocol. 
Cells were observed with an inverted Olympus FSX100 microscope (Olympus, Tokyo, 
Japan). Concentration (in nM) of bound Alizarin Red S was then determined by measuring 
the absorbance at 405 nm and using a calibration curve. Untreated cells (incubated without 
quebecol) were used as a control. The mineralization assays were performed in triplicate 
in two independent experiments. 
 
Statistical analysis 
Unless indicated otherwise, all analyses were performed in triplicate in two independent 
experiments. The data is expressed as means ± standard deviations (SD). Statistical 
analyses were performed using a one-way or two-way analysis of variance with a post hoc 
Bonferroni multiple comparison test (GraphPad Software Inc., La Jolla, CA, USA). All 
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